Columvi achieved a 78.3% complete response rate and 85% overall response rate in relapsed/refractory mantle cell lymphoma ...

A trial evaluating the tamibarotene-Vidaza combination in certain patients with newly diagnosed high-risk MDS will be ...

COVID-19 RNA may induce monocytes to develop cancer-fighting properties, potentially shrinking tumors in certain metastatic ...

Panelists discuss key advice for patients and caregivers navigating advanced prostate cancer, highlighting essential insights ...

Panelists discuss the key takeaways from their experiences in treating advanced prostate cancer, emphasizing valuable lessons ...

Survivorship: it’s a positive word that elicits the idea of success, winning and, as a four-time cancer survivor myself, the ...

Elevated baseline CTC counts are linked to worse overall survival, progression-free survival, and treatment response in cancer patients. In prostate cancer, patients with five or more CTCs at ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

Maria Hicinbothem, Wandaris Ortiz, and Sandi Wetherbee—are being celebrated for their exceptional dedication to patient care, ...

When I was diagnosed with colon cancer, I had a hard time deciding what my legacy should be, but once I realized what it was, ...